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Abstract
Background: Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis.
Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of
trabectedin in a retrospective, multi-center French series of patients with SFTs.
Methods: Patients were mainly identified through the French RetrospectYon database and were treated between
January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor
response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan–Meier method
was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index
(GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the
immediately prior line of treatment (TTPn-1).
Results: Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as
second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST
response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-
control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months
(95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median
GMI was 1.49 (range: 0.11–4.12).
Conclusion: Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.
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Background
Solitary fibrous tumors (SFTs) are rare soft-tissue sarco-
mas with an estimated incidence of < 0.1/100,000/year
[1]. Initially described in pleura, it is now established
that SFTs can occur in almost any extra-pleural site.
They develop mainly in people aged 50–70 years, with a
gender ratio of 1:1.
Solitary fibrous tumors constitute a heterogeneous group
of rare spindle-cell tumors, with an unpredictable course.
Morphologically, SFTs are characterized by a combination
of alternating hypocellular and hypercellular areas, sepa-
rated by hyalinized collagen, with hemangiopericytoma-
like vessels. It should be noted that hemangiopericytomas
(initially described as a distinct neoplasm of pericytic ori-
gin) and SFTs actually constitute a single entity with a mor-
phological continuum [2].
A large majority of cases are benign neoplasms which
have an excellent outcome after complete surgical resec-
tion [3]. However, a small proportion of cases follow an
aggressive course (recurrence after local treatment or
metastatic progression). Increased mitotic activity (≥4
mitoses per 10 high-power fields), greater cellularity, cel-
lular polymorphism, and the presence of necrosis are as-
sociated with malignant behavior [4].
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The standard treatment for localized SFTs is complete
surgical resection. No consensus exists on the treatment
of advanced stages of this disease. Anthracycline-based
chemotherapy or dacarbazine achieve variable response
rates, ranging from 0 to 50 % [5–8]. In addition, interest-
ing results have been reported in small retrospective
series of patients who had received temozolomide plus
bevacizumab [9] or tyrosine kinase inhibitors (sunitinib
[10], sorafenib [11], pazopanib [12], and imatinib [13]).
Trabectedin (Yondelis(®) [PharmaMar S.A., Madrid,
Spain]) is one of the most promising agents to have
been developed over the last two decades, and is now
an approved treatment for patients with anthracy-
cline/ifosfamide-resistant soft-tissue sarcoma and for
those unsuited to these treatments [14, 15]. Objective
responses have already been documented in two case
reports [16, 17].
This retrospective study describes the efficacy and tox-
icity of trabectedin in advanced SFTs.
Methods
Patients
Most patients were identified through the French Retro-
spectYon database, which collected data from patients
treated with trabectedin between January 2008 and
December 2011 in French Sarcoma Group centers. Add-
itional patients were identified through the electronic
databases of certain French cancer centers between
January 2012 and May 2013.
We collected data on: patients’ characteristics at diag-
nosis; disease characteristics including primary tumor
site, extent of disease and pathological features; previous
chemotherapy; and clinical outcomes with trabectedin
therapy.
This study was approved by the ethics committee of
the French Sarcoma Group as well as the scientific
board (which permitted access to the RestrospectYon
database). Access to local databases was granted by the
institutional scientific board of each participating center
belonging to the French Sarcoma Group. All patients
consented in writing to the anonymized assessment and
analysis of clinical data and therapeutic outcome.
Pathology
Diagnosis was established by pathologists at each French
Sarcoma Group center, in accordance with the World
Health Organization classification and criteria [18]. Im-
munologic profile was systematically assessed using
CD34 and other antibodies, depending on histopatho-
logical profile.
Tumors were scored according to mitotic index, cellu-
larity, cytonuclear polymorphism, and necrosis. The mi-
totic index was determined using 10 high-power fields
(×400); necrosis was assessed with a two-area scale
(<50 % or >50 %). Tumor size was also measured.
Treatment
Following the French consensus, trabectedin was given
at the approved initial dose of 1.5 mg/m2 as a 24-h con-
tinuous i.v. infusion every three weeks, along with anti-
emetic prophylaxis and a granulocyte colony-stimulating
factor. Dose reductions (from 1.5 to 1.2 mg/m2, and
then to 1 mg/m2) were decided in cases of toxicity. The
standard number of cycles in patients with disease con-
trol was six, and maintenance therapy was an option
(depending on clinical benefit and the absence of tox-
icity) at the discretion of the physician.
Response assessment
Radiological assessment
Disease status was retrospectively assessed from a CT
scan at baseline and every 2–3 months. Response to
treatment was judged by applying the Response Evalu-
ation Criteria in Solid Tumors (RECIST 1.1) [19]. Dis-
ease control rate (DCR) was defined as complete
response (CR) + partial response (PR) + stable disease
(SD). The clinical benefit rate was defined as DCR ≥
6 months [10].
Growth-modulation index (GMI)
The growth-modulation index (GMI) is a concept intro-
duced in 1998 by Von Hoff [20, 21] to compare succes-
sive times to progression (TTP) in an individual patient.
It is defined as the ratio between the TTP with an ex-
perimental treatment (TTPn) and the TTP with the im-
mediately prior line of treatment (TTPn-1). Because
TTPs tend to be shorter with each treatment line, it has
been proposed that a GMI >1 or even >1.33 could be a
surrogate for drug activity in phase II trials.
Statistical analyses
The data are presented using frequency and percentage
for categorical variables and median and range for con-
tinuous variables.
All survival times were calculated from the date of first
administration of trabectedin, and were estimated by the
Kaplan–Meier method using the following first-event
definitions: progression according to RECIST or death
for progression-free survival (PFS) and death from any
cause for overall survival (OS). Patients who were still
progression-free were censored at the time of their last
follow-up. All statistical analyses were conducted using
STATA 13.0 software.
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Results
Patients
We identified eleven patients with progressive malignant
SFT who were treated with trabectedin between January
2008 and May 2013. Median age at diagnosis was
55 years (range: 37–62 years). Patient and tumor charac-
teristics are summarized in Table 1.
Treatment
All patients had received prior chemotherapy. Trabecte-
din was used as a second-line treatment in eight patients
(72.7 %): six had previously received anthracycline-based
chemotherapy and two a targeted therapy; it was at least
third-line treatment in three patients (27.3 %). The best
RECIST response to a prior therapy was a PR in one pa-
tient (9.1 %) and SD in seven (63.6 %).
All patients were metastatic and had disease progres-
sion at the start of trabectedin therapy (local progres-
sion: 63.6 %; distant progression: 100 %).
Patients received a median of nine cycles of treatment
(range: 2–12). Median treatment duration was 6.1 months
(range: 1–11.5 months). All patients received a standard
dose of 1.5 mg/m2 except for one who was started on
1.2 mg/m2. Two patients (18.2 %) required dose reduction
because of toxicity.
Reasons for stopping trabectedin were disease stabi-
lization after at least six cycles (n = 5, 45.5 %), progres-
sive disease (n = 4, 36.3 %), and toxicity (n = 2, 18.2 %)
(Table 2).
Clinical outcomes after trabectedin therapyData re presented in Table 3.
Response
PR was observed in one patient (9.1 %) and SD in eight
patients (72.7 %). The DCR was 81.8 %. Except for one
patient, SD and PR were confirmed at 6 months. The
clinical benefit rate was thus 72.7 %.
Among the eight patients who received trabectedin as
a second-line treatment, PR was observed in one pa-
tient (12.5 %) and SD in six patients (75 %), with a
DCR of 87.5 %.
The median follow-up was 29.2 months (95 % confi-
dence interval [CI] = 11.7 months; not reached).
The median PFS was 11.6 months (95 % CI = 2.0;
15.2 months) and the median OS was 22.3 months
(95 % CI = 9.1 months; not reached). The 3- and 6-
month PFS were respectively 81.8 % (95 % CI = 44.8;
95.1 %) and 72.7 % (95 % CI = 37.1; 90.3 %). The 12- and
24-month OS rates were respectively 72.7 % (95 % CI =
37.1; 90.3 %) and 37.4 % (95 % CI = 9.5; 66.3 %) (Fig. 1). At
the time of analysis, five patients were alive (45.6 %) and
only one had progressive disease.
GMI
The median TTP with the last-line treatment before tra-
bectedin (median TTP1) was 5.6 months (range: 1.9–
25.3 months). The median growth modulation index was
1.49 (range: 0.11–4.12). For four patients, the GMI was
higher than 2. Data were missing for two patients who
had not progressed after trabectedin but whose predict-
ive GMI was also higher than 2. In total, seven patients
had a GMI (actual or predictive) of >1.33 (63.6 %, 95 %
CI = [30.8–89.1 %]) (Fig. 2).
Toxicity
Grade 3–4 toxicity with trabectedin was observed in
only three patients (27.3 %), and was essentially
hematologic and hepatic (elevation in hepatic transami-
nases > 5× ULN). Two patients (18.2 %) required a dose
reduction and two patients had to stop trabectedin
Table 1 Patient and disease characteristics
Characteristic
Age (years) (median, range) 55 (37–62)
Gender
Male 2 (18.2 %)
Female 9 (81.8 %)
ECOG performance status at diagnosis
0 7 (63.6 %)
1 4 (36.4 %)
Primary tumor site
Pleura 5 (45.5 %)
Abdomen 2 (18.2 %)
Pelvis 2 (18.2 %)
Ovary 1 (9.1 %)
Upper limb 1 (9.1 %)
Pathological characteristics at diagnosis
Mitotic index (/10 HPFa) (median, range) 9 (3–30)
Necrosis
No 6 (54.5 %)




Tumor size (mm) (median, range) 145 (45–180)
Tumor classification at diagnosis
Benign 1 (9.1 %)
Malignant 10 (90.9 %)
Stage of disease at diagnosis
Local 9 (81.8 %)
Metastatic 2 (18.2 %)
a/10 high-power fields
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1a A→ SD → Stab. PD (L + M) 10 Y Stab.
Soraf n°1→ SD → Stab.
Soraf. n°2 → SD → Stab.
Soraf. n°3 → SD → Progr.
2 Soraf PD Progr. PD (M) 9 N Stab.
3 AI PD Progr. PD (L + M) 6 N Progr.
4 A PR Stab. PD (L + M) 12 Y Tox.
5 AI SD Stab. PD (M) 11 N Stab.
6 Ima→ SD → Prog. PD (L + M) 12 N Stab.
AD→ SD → Stab.
Cy→ SD → Progr.
Soraf.→ PD→ Tox.
7 A→ SD → Stab. PD (L + M) 2 N Progr.
Cy→ PD→ Progr.
Suni→ SD → Progr.
Bev + Tmz→ SD → Progr.
8 MAID SD Stab. PD (M) 4 N Tox.
9 AI SD Progr. PD (M) 3 N Progr.
10 AD SD Stab. PD (L + M) 6 N Stab.
11 PLK-Inh. PD Progr. PD (L + M) 11 N Progr.
L local, M metastatic, trab. trabectedin, dose decr. dose decrease, A adriamycin, I ifosfamide, D dacarbazine, M Mesna, Cy cyclophosphamide, Soraf sorafenib, Ima
imatinib, Suni sunitinib, Bev + Tmz bevacizumab + temozolomide, PLK-Inh Polo-Like Kinase inhibitor, SD stable disease, PD progressive disease, Y yes, N no, Stab
disease stabilization, Progr disease progression, Tox toxicity
aPatient 1 received sorafenib three times, in three successive lines of treatment
Table 3 Clinical outcomes after trabectedin therapy









TTP1 (months) TTP2 (months) GMI
1 SD 11.7 N 11.7 Alive 4.9 - -
2 SD 11.6 Y 29.2 Alive 5.6 11.6 2.07
3 SD 3.8 Y 9.1 Dead 1.9 3.8 2.02
4 SD 14.6 Y 22.3 Dead 12.6 14.6 1.16
5 SD 30.9 N 30.8 Alive 7.1 - -
6 SD 11.0 Y 20.9 Alive 3.1 11.0 3.61
7 PD 1.9 Y 7.0 Dead 18.7 1.9 0.11
8 PR 7.5 Y 23.4 Dead 5.1 7.5 1.49
9 PD 2.0 Y 11.1 Dead 7.7 2.0 0.26
10 SD 15.2 Y 17.7 Dead 25.3 15.2 0.6
11 SD 12.3 Y 74.2 Alive 3.0 12.3 4.12
Median 11.6 22.3 5.6 11.6 1.49
SD stable disease, PR partial response, PD progressive disease, GMI growth modulation index, TTP1 time to progression with the prior last-line treatment, TTP2 time
to progression with trabectedin
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because of toxicity, but no toxicity-related deaths were
observed.
Discussion
This study is the first to specifically report on the efficacy
of trabectedin in a relatively large sample of patients with
an advanced malignant solitary fibrous tumor.
We found very interesting results with an overall re-
sponse rate of 9.1 % and a DCR of 81.8 %. The clinical
benefit rate was 72.7 %. However, it should be noted
that there is no standard definition of the duration of
DCR required to qualify as “clinical benefit” in retro-
spective studies. The median PFS of 11.6 months (95 %
CI = 2.0; 15.2 months) and the median OS of 22.3 months
(95 % CI = 9.1 months; not reached) were favorably com-
pared with almost all previous results obtained using con-
ventional chemotherapy or a targeted therapy (Table 4).
The strength of this work was the use of the Growth-
Modulation Index, a relevant parameter which takes into
account the natural course of solitary fibrous tumors.
Based on the fact that SFTs are usually slowly progres-
sive diseases, and the fact that TTPs tend to be shorter
with successive lines of treatment, a high GMI strongly
suggests drug activity.
Cousin et al. showed that GMI was strongly corre-
lated with OS in pre-treated advanced soft-tissue sarco-
mas [22]. More recently, Penel et al. have shown that a
GMI >1.33, as reported in our study, was strongly cor-
related with improved PFS and even OS in advanced
soft-tissue sarcoma patients receiving trabectedin as a
salvage therapy [23].
Interestingly, we found long-lasting responses with tra-
bectedin, even with non-indolent disease. Indeed, two
patients had a long-lasting response in disease that had
been rapidly progressive before introducing trabectedin
(PFS of 11.0 months and 12.3 months after trabectedin,
with a GMI of 3.61 and 4.12, respectively), thus
highlighting the impact of trabectedin on the natural
Fig. 1 Kaplan-Meier curves for progression-free and overall survival from the start of trabectedin therapy
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course of this disease. A further patient had non-
progressive disease for 30 months after starting trabecte-
din therapy (which lasted 9 months) despite presenting
with disease progression only 7 months after starting
anthracycline-based chemotherapy. In this patient, the
predictive GMI was at least 4.28.
Several sources of data suggest the antitumor activity
of trabectedin in translocation-related sarcoma. This has
been clearly established in the case of myxoid round-cell
liposarcoma, where the characteristic chromosomal
translocations of t(12;16)(q13;q11) and t(12;22)(q13;q12)
code for the fusion transcripts FUS-DDIT3 and EWS-
DDIT3, which bind to specific DNA and act as tran-
scription factors for oncoproteins [24]. It has been
shown that the antitumor activity of trabectedin in myx-
oid round-cell liposarcoma was correlated with the ex-
pression of the fusion transcript FUS-DDIT3 by
interfering with the DNA-binding site of the transcript
and by then displacing the transcription factors [25]. Ex-
trapolation of such mechanisms led to the hypothesis
that other translocation-related sarcomas (TRS) that ex-
press other fusion transcripts may have a particular sensi-
tivity to trabectedin. Thus Le Cesne et al. have provided
results from a retrospective pooled analysis of 81 patients
with TRS treated with trabectedin in eight phase II trials.
They reported an overall control rate of 59 %, a median
PFS of 4.1 months, and a median OS of 17.4 months [26].
Promising results have also been reported among TRS pa-
tients pretreated with conventional chemotherapy in a
randomized phase II trial [27].
As regards SFT of the pleura specifically, a recent
study assessed the multimodal management of such tu-
mors (all stages included). Twenty-six of the 68 patients
had recurrence after first-line treatment. Nine received
trabectedin (as a second- or third-line treatment) with a
disease control rate of 78 % and a median TTP of
3.4 months [28]. However, responses were not confirmed
at 3 months and, above all, no data were available for
TTP on the previous line of treatment. Therefore, in
contrast to our study, it is not possible to take into ac-
count the natural course of the disease.
Lastly, recent data have highlighted NAB2–STAT6 fu-
sion, which is a result of inversion within chromosome
12, as a distinct molecular feature of SFTs [29, 30]. In
the context of SFTs, NAB2 gains an activation domain
Fig. 2 Comparison of time to progression with trabectedin (TTP2)
versus time to progression with prior therapy (TTP1) for the 11
patients. The growth modulation index (GMI) is the ratio between
TTP2 and TTP1. Two patients did not progress under trabectedin
(patient 1 and patient 5), so that only a minimum predictive GMI
could be estimated. All in all, seven patients had a GMI (effective or
predictive) > 1.33 (63.6 %, 95 % CI = [30.8–89.1 %])
Table 4 Median PFS (by RECIST) and median OS with other treatments for advanced SFT












31 Anthracycline-based chemo. 25/6 - 4 (range : 2–15) (front-line : 4) 11.5
(range : 3–50)




Park [5] 21a Conventional chemo. (anthracycline-
based/gemcitabine-based/paclitaxel :
15/5/5)
18/7 - 4.6 (95 % CI = 3.7–5.6) (front-line: 4.6
(95 % CI = 4–5.3))
22.8
(95 % CI = 3.1–42.6)
Stacchiotti
[7]
8 Dacarbazine 0/8 - 7 (range : 2–12) -
Park [9] 14 Bevacizumab + temozolomide 9/5 34 10.8 (95 % CI = 8.13-not reached) 24.3
Stacchiotti
[10]
35 Sunitinib 10/25 - 6 (95 % CI = 4.03–8.01) 16
(95 % CI = 12.07–25.9)
Valentin
[11]
5 Sorafenib 0/5 - - 19.7
f-u follow-up, PFS progression-free survival, OS overall survival
aOf 21 patients, 4 received more than one regimen of chemotherapy, for a total of 25 treatments
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from the signaling molecule STAT6, which converts a
transcriptional repressor (NAB2) into a potent transcrip-
tional activator (NAB2–STAT6) of EGR1 (Early Growth
Response 1), a zinc-finger transcription factor. This leads
to the constitutive activation of EGR-mediated transcrip-
tion target genes such as IGF2, FGF2, PDGFD, or FGFR,
which are implicated in the differentiation or prolifera-
tion pathways.
By analogy with myxoid liposarcoma, we can hypo-
thesize that trabectedin interferes with the physical
interaction of the NAB2–STAT6 fusion protein with
EGR1 to ensure its specific anti-tumor activity in SFTs.
However, no experimental data exist to suggest this spe-
cific effect of trabectedin in SFTs.
Even though an important gap remains between pro-
gress in diagnosis and advances in therapy, we are now
better able to relate specific sarcoma subtypes to specific
treatments [14, 31–34]. Trabectedin could become
standard of care in the narrow field of advanced SFTs.
Conclusion
Our data suggest that trabectedin is a very promising
systemic treatment for malignant solitary fibrous tumors
and should be strongly considered as an option along
with other evidence-based therapies such as anthracy-
clines, dacarbazine, bevacizumab + temozolomide, suniti-
nib, and pazopanib.
However, we need further clinical investigations along
with the experimental data associated with dedicated
phase-II trials to understand the mechanisms of action
of trabectedin in this rare sarcoma subtype and to valid-
ate this treatment prospectively in larger series of
patients.
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